Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

Summary

Open-label, multicenter, single arm phase II study, set up in collaboration with the "Réseau d'Expertise Français sur les Cancers ORL Rares" (REFCOR), evaluating the activity and safety of single agent pazopanib in recurrent or metastatic tumors in salivary gland including adenoid cystic carcinoma (ACC) and to exploring the activity and safety of pazopanib in non-adenoid cystic carcinoma (non-ACC).

Timeline

Start

2013-08-26

Primary completion

2015-12-31

Completion

2019-10

Drugs

Indications